← All trials
NCT06878664
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 12, 2025
- Primary completion
- Jan 31, 2029
- Completion date
- Jan 31, 2029
- First posted
- Mar 17, 2025
- Last posted
- Sep 2, 2025
- Enrollment
- 166
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)Lead sponsor
- Institut Gustave RoussyOfficial
- Universidad Complutense de MadridOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.